Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Rare Diseases and Orphan Products: Accelerating Research and Development.

Institute of Medicine (US) Committee on Accelerating Rare Diseases Research and Orphan Product Development; Field MJ, Boat TF, editors.

Washington (DC): National Academies Press (US); 2010.

PMID:
21796826
Free Books & Documents
2.

Advocacy groups and their role in rare diseases research.

Dunkle M, Pines W, Saltonstall PL.

Adv Exp Med Biol. 2010;686:515-25. doi: 10.1007/978-90-481-9485-8_28. Review.

PMID:
20824463
3.

Evidence Brief: The Quality of Care Provided by Advanced Practice Nurses.

McCleery E, Christensen V, Peterson K, Humphrey L, Helfand M.

VA Evidence-based Synthesis Program Evidence Briefs [Internet]. Washington (DC): Department of Veterans Affairs (US); 2011-.
2014 Sep.

PMID:
27606392
Free Books & Documents
4.

Drug development for orphan diseases in the context of personalized medicine.

Brewer GJ.

Transl Res. 2009 Dec;154(6):314-22. doi: 10.1016/j.trsl.2009.03.008. Review.

PMID:
19931198
5.

Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity?

Menon D, Stafinski T, Dunn A, Short H.

Patient. 2015 Feb;8(1):29-39. doi: 10.1007/s40271-014-0106-8. Review.

PMID:
25516506
6.

Advancing Nuclear Medicine Through Innovation.

National Research Council (US) and Institute of Medicine (US) Committee on State of the Science of Nuclear Medicine.

Washington (DC): National Academies Press (US); 2007.

PMID:
20669430
Free Books & Documents
7.

Developing a National Registry of Pharmacologic and Biologic Clinical Trials: Workshop Report.

Committee on Clinical Trial Registries, Board on Health Sciences Policy, Institute of Medicine.

Washington (DC): National Academies Press (US); 2006.

PMID:
26740992
Free Books & Documents
8.

Pharmacokinetics and Drug Interactions in the Elderly and Special Issues in Elderly African-American Populations: Workshop Summary.

Institute of Medicine (US) Committee on Pharmacokinetics and Drug Interactions in the Elderly.

Washington (DC): National Academies Press (US); 1997.

PMID:
20845558
Free Books & Documents
9.

Summary of NIH Medical-Surgical Emergency Research Roundtable held on April 30 to May 1, 2009.

Kaji AH, Lewis RJ, Beavers-May T, Berg R, Bulger E, Cairns C, Callaway C, Camargo CA Jr, Carcillo J, DeBiasi R, Diaz T, Ducharme F, Glickman S, Heilpern K, Hickey R, Hoek TV, Hollander J, Janson S, Jurkovich G, Kellermann A, Kingsmore S, Kline J, Kuppermann N, Lowe R, McLario D, Nathanson L, Nichol G, Peitzman A, Richardson L, Sanders A, Shah M, Shapiro N, Silverman R, Than M, Wilber S, Yealy DM; Roundtable External Participants and Roundtable Steering Committee and Federal Participants..

Ann Emerg Med. 2010 Nov;56(5):522-37. doi: 10.1016/j.annemergmed.2010.03.014.

PMID:
21036293
10.

Clinical guidelines and payer policies on fusion for the treatment of chronic low back pain.

Cheng JS, Lee MJ, Massicotte E, Ashman B, Gruenberg M, Pilcher LE, Skelly AC.

Spine (Phila Pa 1976). 2011 Oct 1;36(21 Suppl):S144-63. doi: 10.1097/BRS.0b013e31822ef5b4. Review.

PMID:
21952186
11.

Orphan drugs policies: a suitable case for treatment.

Drummond M, Towse A.

Eur J Health Econ. 2014 May;15(4):335-40. doi: 10.1007/s10198-014-0560-1. Review.

PMID:
24435513
12.

Development of orphan vaccines: an industry perspective.

Lang J, Wood SC.

Emerg Infect Dis. 1999 Nov-Dec;5(6):749-56. Review.

PMID:
10603207
13.

NIH Roundtable on Opportunities to Advance Research on Neurologic and Psychiatric Emergencies.

D'Onofrio G, Jauch E, Jagoda A, Allen MH, Anglin D, Barsan WG, Berger RP, Bobrow BJ, Boudreaux ED, Bushnell C, Chan YF, Currier G, Eggly S, Ichord R, Larkin GL, Laskowitz D, Neumar RW, Newman-Toker DE, Quinn J, Shear K, Todd KH, Zatzick D; Roundtable External Participants and Roundtable Steering Committee and Federal Participants..

Ann Emerg Med. 2010 Nov;56(5):551-64. doi: 10.1016/j.annemergmed.2010.06.562.

PMID:
21036295
14.

World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ.

World J Methodol. 2014 Sep 26;4(3):163-88. doi: 10.5662/wjm.v4.i3.163. Review.

PMID:
25332915
15.

Evidence Brief: Effectiveness of Intensive Primary Care Programs.

Peterson K, Helfand M, Humphrey L, Christensen V, Carson S.

VA Evidence-based Synthesis Program Evidence Briefs [Internet]. Washington (DC): Department of Veterans Affairs (US); 2011-.
2013 Feb.

PMID:
27606397
Free Books & Documents
16.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
17.

Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives.

Song P, Gao J, Inagaki Y, Kokudo N, Tang W.

Intractable Rare Dis Res. 2012 Feb;1(1):3-9. doi: 10.5582/irdr.2012.v1.1.3. Review.

PMID:
25343064
18.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
19.

U.S. Food and Drug Administration perspective of the inclusion of effects of low-level exposures in safety and risk assessment.

Gaylor DW, Bolger PM, Schwetz BA.

Environ Health Perspect. 1998 Feb;106 Suppl 1:391-4. Review.

PMID:
9539036
20.

Progress and dilemma of contemporary clinical pharmacology.

Herman ZS.

Int J Clin Pharmacol Ther. 2005 Jan;43(1):43-50. Review.

PMID:
15704614
Items per page

Supplemental Content

Support Center